United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold shares under a pre-arranged plan. On June 1, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and received 9,500 shares of common stock.
That same day, she sold 9,500 common shares in multiple open-market transactions at prices generally in the $544–$555 range, as shown by individual trades such as 2,213 shares at $546.2054 per share. These trades were executed pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until either the exercise of up to 1,734,410 stock options that expire on March 17, 2027, or December 31, 2026, whichever occurs first.
After these transactions, Rothblatt directly held 40,513 shares of common stock and 126,410 stock options, and also had indirect ownership of additional common shares through various family trusts and a small position held by her spouse.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 10,000 shares of Common Stock at an exercise price of $117.76 per share and, on the same date, sold 10,000 shares of Common Stock in a series of open-market trades at weighted average prices generally around the mid‑$540s to mid‑$550s per share. The filing states that this option exercise and subsequent share sales were carried out under a pre-arranged Rule 10b5‑1 trading plan. Following these transactions, Edgemond directly owns 18,876 shares of UNITED THERAPEUTICS Common Stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt sold 1,500 shares of common stock in an open‑market transaction. The sale occurred on May 26, 2026 at a weighted average price of $575.9649 per share, leaving her with 43,153 shares directly held afterward.
The shares sold were acquired through an option exercise and the transaction was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. This Form 4/A amendment corrects the transaction code from a purchase to the proper sale code while keeping the disposition and share counts consistent.
UTHR notice shows a planned sale tied to an exercise of stock options: 199,500 shares to be sold on 06/01/2026 for cash. The filing also lists multiple prior 10b5-1 sales by Martine Rothblatt of 9,500 shares on many dates in March–May 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On May 29, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open‑market trades at weighted average prices in the mid‑$550s, all pursuant to a pre‑arranged 10b5‑1 trading plan. Following these transactions, she directly holds 40,513 shares of common stock and 135,910 stock options, in addition to indirect holdings through family trusts and her spouse.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of Common Stock at a price of $117.76 per share and, on the same date, sold 10,000 shares of Common Stock in a series of open-market transactions.
The reported sales occurred at weighted average prices ranging from approximately $561.48 to $571.48 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following these transactions, Edgemond directly holds 18,876 shares of Common Stock and 50,000 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share and sold 9,500 shares in multiple open-market transactions around $561–$572 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to run until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company stock. On May 27, 2026, she exercised stock options to acquire 9,500 shares of common stock at a strike price of $146.03 per share and sold 9,500 shares in open-market trades at prices mostly around the high $570s per share.
After these transactions, Rothblatt directly holds 40,513 shares of common stock and also has additional indirect holdings through family trusts and her spouse. The filing notes that the option exercise and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. He exercised 10,000 stock options for Common Stock at an exercise price of $117.76 per share, then sold 10,000 shares of Common Stock in multiple open-market sales on May 26, 2026.
The sales were executed in numerous trades at weighted average prices within ranges from about $558.79 to $578.53 per share and were carried out under a Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, he directly holds 18,876 shares of Common Stock and continues to hold stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported a mix of option exercises and share trades in company stock. On May 26, 2026 she exercised stock options for 9,500 shares of common stock at a conversion price of $146.03 per share, then carried out open-market transactions involving 8,000 shares sold and 1,500 shares purchased, according to the filing’s transaction summary.
The open-market trades occurred at weighted average prices generally in the $560–$580 range per share. A footnote states these option exercises and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Rothblatt also reports significant indirect holdings in family trusts and through a spouse, with individual trust positions such as 324,443 shares and 249,108 shares of common stock.